From: Immunotherapy in endometrial cancer: rationale, practice and perspectives
Mechanism of action | NCI identifie | Agents | Phase | Setting/cancer type | Patient number | Subtype contribution | Outcomes | Status |
---|---|---|---|---|---|---|---|---|
anti-PD-1 antibody | NCT01876511 | Pembrolizumab | II | Advanced MMR-deficient Cancers including EC | Total:86, EC:15 | all MMR-d | ORR, DCR, PR, SD, PD | published |
NCT02054806 | Pembrolizumab | Ib | PD-L1 positive Advanced EC | 24 | POLE:1, MSI-high:1, MSS:17, Not evaluable:5 | ORR, median PFS, median OS, PR, SD, PD | published | |
NCT02628067 | Pembrolizumab | II | Noncolorectal MMR-d cancers including EC | Total:233, EC:49 | all MMR-d | CR, PR, ORR, median PFS, median OS, median DOR | published | |
NCT02465060 | Nivolumab | II | Noncolorectal MMR-d cancers including EC | Total:42, EC:13 | all MMR-d | ORR, CR, PR, SD, PD, median PFS | published | |
Abti-PD-1 antibody+ Antiangiogenic therapy | NCT03015129 | Pembrolizumab+ Lenvatinib | II | rEC | 108 | MSI:11,MSS:94 | ORR, PFS, OS, DOR | published |
anti-PD-L1 antibody | NCT01375842 | Atezolizumab | Ia | rEC | 15 | MSI-H:1, MSS:7, unknown for MMR status:7 | ORR, PFS,OS | published |
NCT02912572 | Avelumab | II | rEC | 33 | MSS:16, MSI:17 | OR, PFS6 | published | |
ACTRN12617000106336 | Durvalumab | II | advanced EC | 71 | MSI:36, MSS:35 | OTR, PFS, OS | published | |
anti-PD-L1 antibody+ anti-CTLA-4 | NCT03015129 | Durvalumab and Tremelimumab versus Durvalumab Monotherapy | II | rEC and Endometrial Carcinosarcoma | Total:56, EC:41 | MSI:5, MSS:48, unknown:3 | ORR, median DOR, PFS, PFS rate at 24 wks | published |
tumor antigen loaded DC cancer vaccine | EudraCT 2009-016868-37 | WT1mRNA-electroporated mature DCs (DCm-WT1- RNA) | I/II | Uterine Tumor | Total:6, serous EC:3 | NA | PFS, OS, Oncologic outcome (CT Scan, CA125), Immune Response (WT1-specific T-cells, NK cells) | published |
peptide cancer vaccine+ anti-tumor cytokine | NCT01580696 | E39 peptide waccine+ GM-CSF | I/IIa | Ovarian and EC | Total:51, EC:9 | NA | DFS | published |
Chimeric peptide cancer vaccine | BB-IND-9803 | B-cell epitopes of HER2-Th (MVF) epitope chimeric peptide vaccine | I | Metastatic and/or Recurrent Solid Tumors including EC | Total:24, EC:1 | NA | antibody response, PR, SD | published |
nucleic acid-based cancer vaccine+ anti-PD-1 antibody | NCT03313778 | mRNA-4157 vaccine+ Pembrolizumab | I | Resectable/Unresectable Solid Tumors including EC | Total:33, EC:1 | MSI | PR, SD, PD, neoantigen-specific T cell response | published |
ACT+ hyperthermia+ anti-PD-1 antibody/ chemotherapy | NCT03757858 | Autologous Adoptive T cell Transfer+ Hyperthermia+ Pembrolizumab/ Chemotherapy | I | Advanced Solid Tumors including EC | Total:33, EC:5 | NA | ORR, DCR, Clinical Response (CR, PR, SD, PD) | published |
anti-PD-1 antibody | NCT02628067 | Pembrolizumab | II | Advanced Solid Tumors including EC | NA | NA | ORR | Recruiting |
NCT02630823 | Pembrolizumab | I | Surgically Resectable EC | NA | NA | AEs | Active, not recruiting | |
NCT02728830 | Pembrolizumab | I | Gynecologic Cancers including EC | NA | NA | Fold change in tumor Immune Infiltrates | Active, not recruiting | |
NCT02899793 | Pembrolizumab | II | Advanced, Recurrent or Metastatic EC | NA | POLE,MSI | ORR,AEs | Recruiting | |
NCT03241745 | Nivolumab | II | Metastatic or Recurrent Uterine Cancer | NA | all dMMR(EC) | PFS | Recruiting | |
NCT03568539 | IBI308 | Ib | Advanced or Metastatic Solid Tumors including EC | NA | NA | Overall Response Rate,CR,PR | Active, not recruiting | |
anti-PD-1 antibody+ Surgery | NCT03694834 | Pembrolizumab+ Hysterectomy+ Surgical staging | I | Early Stage, High Grade Obesity-driven EC | NA | NA | TIL | Suspended |
anti-PD-1 antibody+ Surgery+ Chemotherapy | NCT03932409 | Pembrolizumab+ Vaginal Cuff Brachytherapy+ Paclitaxel+ Carboplatin | Ib | High Intermediate Risk EC | NA | NA | Proportion of patients completing three cycles | Not yet recruiting |
anti-PD-1 antibody+ Chemotherapy | NCT02549209 | Pembrolizumab+\Carboplatin+ Paclitaxel | II | Advanced, Recurrent or Metastatic EC | NA | NA | ORR | Recruiting |
NCT03276013 | Pembrolizumab+ Doxorubicin | II | Advanced, Recurrent or Metastatic EC | NA | NA | PFS | Active, not recruiting | |
NCT03981796 | Dostarlimab+ Carboplatin- Paclitaxel | III | Advanced, Recurrent or Metastatic EC | NA | will do MMR evaluation | PFS | Recruiting | |
NCT03914612 | Pembrolizumab+ Paclitaxel+ Carboplatin | III | Stage III/IV or Recurrent EC | NA | will do MMR evaluation | PFS | Recruiting | |
anti-PD-1 antibody+Radiotherapy | NCT04214067 | Pembrolizumab+ Radiation therapy | III | High Intermediate Risk Endometrioid EC | NA | all dMMR | 3 year recurrence -free survival | Not yet recruiting |
NCT03955978 | Dostarlimab+ Standard of Care Definitive Radiation | I | Inoperable EC | NA | NA | Safety and tolerability | Recruiting | |
anti-PD-1 antibody+PARP inhibitor | NCT03016338 | Dostarlimab+ Niraparib | II | Advanced,Recurrent or Metastatic EC | NA | NA | Clinical benefit rate | Recruiting |
NCT03572478 | Nivolumab+ Rucaparib | Ib/IIa | Advanced or Recurrent EC and Metastatic Castrate-Resistant Prostate Cancer | NA | NA | DLT rate | Recruiting | |
anti-PD-1 antibody+ Antiangiogenic therapy | NCT04197219 | Pembrolizumab+ Axitinib | II | Advanced, Recurrent or Metastatic EC | NA | all dMMR | ORR,CR, PR | Not yet recruiting |
NCT02501096 | Pembrolizumab+ Lenvatinib | Ib/II | metastatic Solid Tumors including EC | NA | NA | MTD,ORR,DLT | Active, not recruiting | |
NCT03367741 | Nivolumab+ Cabozantinib | II | Advanced, Recurrent or Metastatic EC | NA | NA | PFS | Suspended | |
NCT03517449 | Pembrolizumab+ Lenvatinib | III | Advanced, Recurrent or Metastatic EC | NA | will do MMR evaluation | PFS,OS | Active, not recruiting | |
NCT03884101 | Pembrolizumab+ Lenvatinib | III | Advanced, Recurrent or Metastatic EC | NA | will do MMR evaluation | PFS,OS | Recruiting | |
NCT04157491 | anti-PD-1 antibody+ Anlotinib | II | Advanced, Recurrent or Metastatic EC | NA | NA | ORR,CR, PR | Recruiting | |
anti-PD-1 antibody+IDO inhibitor | NCT02178722 | Pembrolizumab+ Epacadostat (INCB024360) | I/II | Cancers including EC | NA | NA | TEAEs, ORR | Active, not recruiting |
NCT04106414 | Nivolumab+ BMS-986205 | II | Recurrent or Persistent EC or Endometrial Carcinosarcoma | NA | will do MMR evaluation | Best overall response rate | Recruiting | |
anti-PD-1 antibody+ anti-CTLA-4 antibody | NCT02982486 | Nivolumab+ Ipilimumab | II | Nonresectable or Metastatic EC and Sarcoma | NA | all dMMR | CR,PR | Not yet recruiting |
anti-PD-1 antibody+ 4-1BB antibody | NCT03917381 | GEN1046 | I/II | Malignant Solid Tumors including EC | NA | NA | DLT,AEs, Safety laboratory parameters | Recruiting |
anti-PD-1 antibody+ CFTR inhibitor | NCT04014530 | Pembrolizumab+ Ataluren | I/II | Metastatic EC and Colorectal Adenocarcinoma | NA | all dMMR(EC) | ORR | Recruiting |
anti-PD-1 antibody+ Dual Adenosine Receptor (A2aR/A2bR) Antagonist | NCT03629756 | Zimberelimab (AB122)+ AB928 | I | Advanced Solid Tumors including EC | NA | NA | DLTs,AEs | Recruiting |
anti-PD-1 antibody+ FRα ADC | NCT03835819 | Pembrolizumab+ Mirvetuximab Soravtansine (IMGN853) | II | Advanced, Recurrent or Metastatic EC | NA | all MSS | ORR, PFS | Recruiting |
anti-PD-1 antibody+ Hormone | NCT04046185 | Toripalimab+ Progesterone | I | Early EC (preserve fertility) | NA | NA | Pathologic complete /patrial remission rate | Not yet recruiting |
anti-PD-1 antibody+IAP | NCT04122625 | Nivolumab+ Mimetic Debio 1143 | Ib/II | Solid Tumors including EC, progressed during/immediately after anti-PD-1/PD-L1 treatment | NA | known MMR status | ORR | Recruiting |
anti-PD-1 antibody+ Immune Modulatory Cocktail+ Radiotherapy+ Food supplement | NCT03192059 | Pembrolizumab+ Immune Modulatory Cocktail (Vitamin D+ Lansoprazole Teva+ Cyclophosphamide+Aspirine,) +Radiotherapy +Curcumin | II | Refractory or Recurrent EC, CC, Uterine sarcoma | NA | NA | ORR | Recruiting |
anti-PD-1 antibody+ multi-targeted RTK inhibitor | NCT03827837 | Camrelizumab+ Famitinib | II | Advanced RCC/UC/CC/EC and Recurrent OC | NA | NA | Overall response rate | Recruiting |
anti-PD-1 antibody+ PVRIG antibody | NCT03667716 | COM701 monotherapy or COM701+ Nivolumab | Ia/b | Advanced or Metastatic Solid Tumors including EC | NA | NA | AEs ,DLTs,MTD, RDFE | Recruiting |
anti-PD-L1 antibody | NCT02725489 | Durvalumab+Vigil | II | Advanced Women's Cancers including EC | NA | NA | AEs | Active, not recruiting |
NCT03212404 | Cosibelimab | I | Advanced or Metastatic Solid Tumors including EC | NA | NA | DLT,AEs,ORR | Recruiting | |
anti-PD-L1 antibody+ Chemotherapy | NCT02914470 | Atezolizumab+ Carbplatin+ Cyclophophamide | Ib | Advanced Gynaecologic Cancer including EC,BC | NA | NA | Toxicity, Incidence of toxicity,AEs | Active, not recruiting |
NCT03503786 | Avelumab+ Carboplatin+ Paclitaxel | II | Advanced, Recurrent or Metastatic EC | NA | NA | PFS | Not yet recruiting | |
NCT03603184 | Atezolizumab+ Paclitaxel+ Carboplatin | III | Advanced, Recurrent or Metastatic EC | NA | Will do MMR evaluation | OS,PFS | Recruiting | |
anti-PD-L1 antibody+ Antiangiogenic therapy | NCT03170960 | Atezolizumab+ Cabozantinib | Ib | Advanced or Metastatic Solid Tumors including EC | NA | NA | MTD/RD,ORR | Recruiting |
NCT03526432 | Atezolizumab+ Bevacizumab | II | Advanced, Recurrent or Metastatic EC | NA | will do MMR evaluation | Number of patients who experience CR or PR | Recruiting | |
anti-PD-L1 antibody+PARP inhibitor | NCT02912572 | Avelumab/ Avelumab+ Talazoparib | II | Advanced, Recurrent or Metastatic EC | NA | POLE,MSI,MSS | PFS | Recruiting |
NCT03101280 | Atezolizumab+ Rucaparib | Ib | Advanced Gynecologic Cancers inclunding EC, TNBC | NA | NA | AEs,DLTs,RP2D,Number of Dose Modifications due to AEs | Active, not recruiting | |
NCT03951415 | Durvalumab+ Olaparib | II | Advanced, Recurrent or Metastatic EC | NA | NA | PFS | Recruiting | |
anti-PD-L1 antibody+ Chemotherapy+ PARP inhibitor | NCT04269200 | Durvalumab+ Carboplatin+ Paclitaxel+ Olaparib | III | Advanced, Recurrent or Metastatic EC | NA | will do MMR evaluation | PFS | Not yet recruiting |
anti-PD-L1 antibody+ Antiangiogenic therapy+ PARP inhibitor | NCT03694262 | Atezolizumab+ Bevacizumab+ Rucaparib | II | Advanced, Recurrent or Metastatic EC | NA | will do MMR evaluation | Overall Response Rate | Recruiting |
anti-PD-L1 antibody+ IDO inhibitor | NCT02471846 | Atezolizumab+ GDC-0919 | Ib | Advanced or Metastatic Solid Tumors including EC | NA | NA | DLTs,AEs | Completed |
anti-PD-L1 antibody+ anti-CTLA-4 antibody | NCT03015129 | Durvalumab+ Tremelimumab | II | Persistent or Recurrent EC and Endometrial Carcinosarcoma | NA | NA | Overall Response Rate | Recruiting |
anti-PD-L1 antibody+ anti-CTLA-4 antibody+ Radiotherapy | NCT03277482 | Durvalumab+ Tremelimumab+ Radiotherapy | I | Recurrent Gynecologic Cancer including EC | NA | NA | MTD | Recruiting |
anti-PD-L1 antibody+ anti-5T4 antibody-superantigen fusion protein | NCT03983954 | Durvalumab+ Naptumomab | Ib/II | Advanced or Metastatic Solid Tumors including EC | NA | NA | AEs,MTD,RP2D | Recruiting |
Dual Blockade of PD-1 and CTLA-4 | NCT03517488 | XmAb20717 | I | Advanced Solid Tumors including EC | NA | all dMMR(EC) | AEs | Recruiting |
anti-B7-H4 antibody | NCT03514121 | FPA150 | Ia/b | Advanced or Metastatic Solid Tumors including EC | NA | NA | MTD,RD,AEs | Active, not recruiting |
anti-LAG-3 antibody | NCT03538028 | INCAGN02385 | I | Advanced or Metastatic Solid Tumors including EC | NA | all dMMR(EC) | TEAEs | Recruiting |